Central inhibition of oxytocin receptors using atosiban (4.5 μg in 5 μl, i.c.v.), or retosiban (3 mg/kg, i.v.), prevented the MI-induced increase in SNA and reduced the incidence of ventricular arrhythmias and mortality. Here, OXTR is linked to myocardial infarction.